Clinical genetic testing company Natera has hired Minetta Liu as its new chief medical officer of oncology, where she’ll spearhead proving the clinical utility of Signatera, a tumor DNA blood test. Liu will replace Alexey Aleshin, who is moving into the role of general manager of early cancer detection.
Most recently, Liu was professor of oncology and chair of research in the department of oncology at Mayo Clinic. She was also co-leader of the Genomics in Action Strategy Priority for the Center of Individualized Medicine.
“I am very pleased to welcome Dr. Liu to Natera,” Solomon Moshkevich, general manager of oncology at Natera, said in a statement. “As a highly regarded and accomplished leader in the field, her vision and expertise will be invaluable as we pursue our mission to help cancer patients live longer, happier lives.”
